Why the study?
It was unknown whether measuring HbA1c levels and/or glycaemic variability could identify diabetic patients with high platelet reactivity who may benefit from tailored antiplatelet or glucose-lowering strategies.
Do glycaemic variability and HbA1c levels identify high platelet reactivity in type 2 diabetic patients undergoing PCI on clopidogrel?
Do glycaemic variability and HbA1c levels identify high platelet reactivity in type 2 diabetic patients undergoing PCI on clopidogrel?
Answers are grounded in this paper and cite their sources.
Combining glycaemic variability and HbA1c provides the highest diagnostic accuracy for identifying high platelet reactivity in well-controlled type 2 diabetic patients on clopidogrel after PCI.
BACKGROUND: Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help identifying diabetic patients at higher risk deserving tailored antiplatelet and/or glucose lowering strategies is unknown. We aimed to investigate the relationship between GV, HbA1c levels and platelet reactivity in patients with type 2 diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI). METHODS: Platelet reactivity was measured in type 2 DM patients using VerifyNow P2Y12 assay. HPR was defined as P2Y12 Reaction Unit (PRU) > 240. GV was expressed through mean amplitude of glycaemic excursions (MAGE) and coefficient of variance (CV) by using the iPro™ continuous glucose recorder. RESULTS: Thirty-five patients (age 70 ± 9 years, 86% male, mean HbA1c 7.2 ± 1.0%) on clopidogrel therapy were enrolled. HbA1c was independently associated with HPR (OR 7.25, 95% CI 1.55-33.86, p = 0.012). Furthermore, when factored into the model, GV indexes provided independent (OR 1.094, 95% CI 1.007-1.188, p < 0.034) and additional (p < 0.001) diagnostic significance in identifying diabetic patients with HPR. CONCLUSIONS: Glyco-metabolic state significantly correlates with HPR in well-controlled type 2 DM patients on clopidogrel therapy. HbA1c identifies patients at higher thrombotic risk but the highest diagnostic accuracy is achieved by combining GV and HbA1c. Whether individualized antithrombotic and glucose-lowering therapies based on the assessment of these parameters may reduce the incidence of thrombotic events in patients undergoing PCI should be further investigated.
No takes yet. Share an insight, caveat, or question.
Nusca et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: